Oculis Holding AG
NASDAQOCS entered the weekend down 23% — a collapse driven by a single late-Friday announcement. The entire OCS story this week resolves to one event. After Friday's close, Oculis reported topline results from the DIAMOND-1 and DIAMOND-2 Phase 3 trials of OCS-01 eye drops in diabetic macular edema. The primary endpoint — best-corrected visual acuity — was not met in either study. The…
OCS cost to borrow doubles to 4.93% — up 104% in one week as stock rallies 19%.
Snapshot as of 30 May 2026
OCS entered the weekend down 23% — a collapse driven by a single late-Friday announcement. The entire OCS story this week resolves to one event. After Friday's close, Oculis reported topline results from the DIAMOND-1…
OCS arrives at Wednesday's Q1 results riding one of the sharpest rallies in its recent history — up 20% over the past month and 16% in the last week alone to $32.65 — making tomorrow's print far more consequential than…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OCS — free to start on ORTEX.
Sign up for free →Open OCS on ORTEX